(E)-1-fluoro-1-tributylstannyl-2-phenylethene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-1-fluoro-1-tributylstannyl-2-phenylethene
• 英文别名: (E)-tributyl(1-fluoro-2-phenylvinyl)stannane；tributyl-[(E)-1-fluoro-2-phenyl-vinyl]stannane
• 化学式: C₂₀H₃₃FSn
• 分子量: 411.19
• InChiKey: VJAUOMHJLITUGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.39
• 重原子数：
  22
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-1-fluoro-1-tributylstannyl-2-phenylethene 在 copper(l) iodide 、 四(三苯基膦)钯 、 氯甲酸乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以89%的产率得到(1Z,3Z) 2,3-difluoro-1,4-diphenyl-buta-1,3-diene
  参考文献：
  名称：

  Coupling of 2-Substituted 1-Fluorovinylstannanes with Organic Halides Catalyzed by Palladium(0)/Copper(I) Iodide. A Mild and Stereospecific Method to Monofluoroolefins

  摘要：

  The palladium-catalyzed cross-coupling reactions of (E)- or (Z)-1-fluorovinylstannanes with aryl iodides and vinyl iodides provide good yields of stereoisomerically pure substituted fluoroolefins with retention of the double bond geometry. The reaction takes place with copper(I) iodide present as a cocatalyst at ambient temperature or in refluxing tetrahydrofuran and is tolerant of a variety of functional groups. Highly functionalized and stereoisomerically pure monofluorovinyl ketones also were obtained under mild conditions by the coupling of 1-fluorovinylstannanes with acid chlorides. (1)H-{(19)F} NOE NMR experiments unequivocally established the stereochemistry of the coupling products E-14 and Z-14.

  DOI：

  10.1021/jo982200n
• 作为产物：
  描述：

  苯甲醛 在 偶氮二异丁腈 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 7.33h， 生成 (E)-1-fluoro-1-tributylstannyl-2-phenylethene
  参考文献：
  名称：

  高度立体选择性的单氟烯烃：易于从三氟甲基α-氟代芳基磺酰基宝石-二醇中获得（E）-α-氟代芳基乙烯基砜

  摘要：

  已经开发了在温和的反应条件下利用三氟甲基α-氟化芳基磺酰基宝石-二醇和芳基醛的出色的立体选择性直接合成三取代（E）-α-氟化芳基乙烯基砜的方法，该方法可通过E-异构体以高收率获得α-氟化芳基乙烯基砜。只要。所需产物可以通过脱苯磺酰基方法进一步转化为更有用的氟代烯烃。

  DOI：

  10.1016/j.tetlet.2020.151964

文献信息

• COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
  申请人：Charrier Jean-Damien

  公开号：US20120035408A1

  公开（公告）日：2012-02-09

  The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula V: wherein the variables are as defined herein.

  本发明涉及用作ATR蛋白激酶抑制剂的吡嗪和吡啶化合物。本发明还涉及包含该发明化合物的药学上可接受的组合物；使用该发明化合物治疗各种疾病、障碍和病症的方法；制备该发明化合物的过程；制备该发明化合物的中间体；以及在体外应用中使用该化合物的方法，例如研究生物和病理现象中的激酶、通过此类激酶介导的细胞内信号转导途径的研究以及新的激酶抑制剂的比较评估。本发明化合物的化学式为V，其中变量的定义如本文所述。
• Compounds useful as inhibitors of ATR kinase
  申请人：Charrier Jean-Damien

  公开号：US09062008B2

  公开（公告）日：2015-06-23

  The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula V: wherein the variables are as defined herein.

  本发明涉及用作ATR蛋白激酶抑制剂的吡嗪和吡啶化合物。本发明还涉及包含本发明化合物的药学上可接受的组合物；使用本发明化合物治疗各种疾病、疾病和病况的方法；制备本发明化合物的过程；制备本发明化合物的中间体；以及在体外应用中使用化合物的方法，如研究生物和病理现象中的激酶、介导这些激酶的细胞内信号转导途径的研究，以及新的激酶抑制剂的比较评估。本发明化合物具有公式V：其中变量如本文所定义。
• Palladium/Copper (I) halide-cocatalyzed stereospecific coupling of 1-fluorovinylstannanes with aryl iodides and acyl chlorides
  作者：Chen Chen、Keith Wilcoxen、Kyung-il Kim、James R. McCarthy

  DOI：10.1016/s0040-4039(97)10003-x

  日期：1997.11

  Cross-coupling of 1-fluorovinylstannanes with aryl iodides or acyl chlorides, cocatalyzed by palladium and copper (I) iodide proceeded under mild conditions to give substituted fluoro olefins and alpha-fluoro-alpha,beta-unsaturated ketones, respectively, in good yields with retention of configuration. (C) 1997 Elsevier Science Ltd.
• Synthesis of the Multisubstituted Halogenated Olefins via Cross-Coupling of Dihaloalkenes with Alkylzinc Bromides
  作者：Daniela Andrei、Stanislaw F. Wnuk

  DOI：10.1021/jo051980e

  日期：2006.1.1

  The 1-fluoro-1-haloalkenes undergo Pd-catalyzed Negishi cross-couplings with primary alkylzinc bromides to give multisubstituted fluoroalkenes. The alkylation was trans-selective giving pure Z-fluoroalkenes in most cases. The highest yields were obtained with Pd-2(dba)(3) and PdCl2(dppb) catalysts but the best stereochemical outcome was obtained with less reactive Pd(PPh3)(4). The tertiary alkylzincs also produced desired fluoroalkenes in high yields. Coupling of beta,beta-dichloro styrene with organozinc reagent resulted in the formation of monocoupled product.
• [EN] COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE<br/>[FR] COMPOSÉS UTILISABLES EN TANT QU'INHIBITEURS DE LA KINASE ATR
  申请人：VERTEX PHARMA

  公开号：WO2011143423A3

  公开（公告）日：2012-03-01